11,457 reports of this reaction
5.5% of all SACUBITRIL AND VALSARTAN reports
#1 most reported adverse reaction
HYPOTENSION is the #1 most commonly reported adverse reaction for SACUBITRIL AND VALSARTAN, manufactured by Novartis Pharmaceuticals Corporation. There are 11,457 FDA adverse event reports linking SACUBITRIL AND VALSARTAN to HYPOTENSION. This represents approximately 5.5% of all 209,561 adverse event reports for this drug.
SACUBITRIL AND VALSARTAN has an overall safety score of 85 out of 100. Patients taking SACUBITRIL AND VALSARTAN who experience hypotension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOTENSION is moderately reported among SACUBITRIL AND VALSARTAN users, representing a notable but not dominant share of adverse events.
In addition to hypotension, the following adverse reactions have been reported for SACUBITRIL AND VALSARTAN:
The following drugs have also been linked to hypotension in FDA adverse event reports:
HYPOTENSION has been reported as an adverse event in 11,457 FDA reports for SACUBITRIL AND VALSARTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOTENSION accounts for approximately 5.5% of all adverse event reports for SACUBITRIL AND VALSARTAN, making it one of the most commonly reported side effect.
If you experience hypotension while taking SACUBITRIL AND VALSARTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.